Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Our drug candidates are based upon Leukothera® (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera® are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.
Hematologic diseases (leukemia, lymphoma, and multiple myeloma) are cancers of white blood cells that are often deadly and difficult to treat. Preclinical efficacy studies have shown that Leukothera™ is highly effective at eliminating malignant white blood cells both under laboratory conditions and in animals.Read More
Autoimmune and inflammatory diseases comprise a range of disorders that are characterized by the abundant presence of chronically activated WBCs. Leukothera® specifically targets these activated WBCs without affecting healthy cells and tissues.Read More
HIV infects white blood cells and can hide from our immune system within them. Current therapies can target replicating virus, but do not eliminate the HIV-infected cells. These infected white blood cells are what prevent any current drugs from curing HIV infection.Read More